Search Results - trail

4 Results Sort By:
Agonistic Human Monoclonal Antibodies against Death Receptor 4 (DR4)
Abstract: The National Cancer Institute is seeking parties interested in licensing human monoclonal antibodies (mAbs) that bind to death receptor 4 ("DR4"). The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and its functional receptors, DR4 and DR5, have been recognized as promising targets for cancer treatment.  Therapeutics...
Published: 5/22/2024   |   Inventor(s): Dimiter Dimitrov, Yang Feng
Keywords(s): ANTIBODY, death receptor, Dr4, Mab, TRAIL
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
Analogues of Withanolide E Sensitize Cancer Cells Toward Apoptosis
Abstract: The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) protein has been a target of interest in cancer therapy because it plays a large role in inducing cell apoptosis in cancer cells but not in normal cells.  Although TRAIL has been reported to successfully target certain tumor cells which are resistant to traditional chemotherapy...
Published: 12/4/2024   |   Inventor(s): Thomas Sayers, Alan Brooks, Curtis Henrich, Poonam Tewary, James McMahon, Leslie Gunatilaka, Yaming Xu, Kithsiri Wijeratne
Keywords(s): APOPTOSIS, Immunotherapy, TLR3 ligands, TRAIL, withanolide
Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration
Use of Cucurbitacins and Withanolides for the Treatment of Cancer
Abstract: Certain members of the cucurbitacin and Withanolide family have been identified that can sensitize some tumor cell lines to cell death (apoptosis) on subsequent exposure of the cells to pro-apoptotic receptor agonists (PARAS) of the TRAIL "death receptors". These PARAS include TRAIL itself, and agonist antibodies to two of its receptors death...
Published: 5/22/2024   |   Inventor(s): Thomas Sayers, Kirk Gustafson, Karen Erickson, Alan Brooks, Curtis Henrich, Nancy Booth
Keywords(s): cucurbitacin, Immunotherapy, mapatumamab, TRAIL, withanolide
Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing
Use of beclin 1 Inhibitors, including 17-hydroxy Wortmannin, to Treat TRAIL-resistant Cancer
This technology includes the use of a beclin 1 inhibitor, 17-hydroxy Wortmannin, for the treatment of TRAIL-resistant colon cancer. TRAIL (TNF-related apoptosis-inducing ligand) binds to death receptors (DR4/DR5) and activates apoptosis in cancer cells. Multiple clinical trials have focused on promoting TRAIL-induced death but have had a lack of efficacy...
Published: 10/28/2024   |   Inventor(s): Sheng Dai, Wei Zheng
Keywords(s): 1, 17-hydroxy, Autophagy, Beclin, CANCER, Cells, COLON, Increased, Inhibitions, Overcomes, Resistance, TRAIL, VCXXXX, WIXXXX, WKXXXX, Wortmannin, XEXXXX
Category(s): TherapeuticArea > Oncology, Application > Research Materials, Application > Therapeutics